Bloomberg Intelligence
Amicus' Crowley on Expanding Pipeline for Rare Diseases (Audio)
This episode isn’t summarized yet
Create a free account and summarize it. In a few minutes you’ll have the key takeaways and a section-by-section summary.
Show notes
(Bloomberg) -- Taking Stock with Kathleen Hays and Pimm Fox. GUEST: HEALTHCARE: John Crowley, CEO of Amicus Therapeutics, on expanding its pipeline of treatments for rare and orphan diseases.
See omnystudio.com/listener for privacy information.